SciClone CEO Friedhelm Blobel On Building A Specialty Pharma Business In China: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
On the sidelines of the annual JP Morgan Healthcare Conference, Blobel talks about China price cuts, FCPA compliance, renegotiating promotional contracts with Sanofi, Pfizer and Baxter, and SciClone’s plans for in-licensing the next Zadaxin.
You may also be interested in...
China's Outsource Sales Model Takes A Big Step: SciClone Takes Out NovaMed
SciClone Pharmaceuticals will significantly broaden its commercial footprint across China by acquiring privately owned, Shanghai-based specialty pharma NovaMed Pharmaceuticals for close to $62 million plus potential earnouts in a deal that closed April 18
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.